Table 5 Clinical characteristics according to treatment with antimalarials at the study point
From: Predictors of major infections in systemic lupus erythematosus
| Â | Antimalarials | P value | |
|---|---|---|---|
| Â | Yes (n = 146) | No (n = 103) | Â |
Age at diagnosis (years) | 34 (14) | 40 (18) | <0.01 |
Female sex | 131/146 (89) | 63/103 (86) | 1.00 |
Nephritis ever | 35/146 (24) | 50/103 (48) | <0.01 |
Lung involvement ever | 11/146 (7.5) | 13/103 (12.6) | 0.26 |
Thrombocytopenia ever | 24/146 (16) | 17/103 (26) | 0.08 |
Leukopenia ever | 94/146 (64) | 85/103 (82) | <0.01 |
Anti-DNA antibodies ever | 96/146 (66) | 67/103 (65) | 1.00 |
Low complement at study point | 48/143 (34) | 40/101 (40) | 0.40 |
Prednisone at study point | 89/146 (61) | 63/103 (62) | 1.00 |
Azathioprine at study point | 18/146 (12) | 18/103 (18) | 0.34 |
Cyclophosphamide at study point | 2/146 (1) | 3/103 (3) | 0.69 |
Methotrexate at study point | 12/146 (8) | 3/103 (3) | 0.144 |
Mycophenolate at study point | 6/146 (45) | 0/103 (0) | 0.04 |
SDI = 0 | 121/146 (83) | 61/103 (59) | Â |
SDI = 1 to 2 | 25/146 (17) | 35/103 (34) | 0.001 |
SDI >2 | 0/146 (0) | 7/103 (7) | Â |
SLEDAI at diagnosis | 9 (1 to 22) | 9 (2 to 25) | 0.94 |
SLEDAI at study point | 4 (0 to 21) | 3 (0 to 24) | 0.84 |
SLEDAI at diagnosis >12 | 33/143 (23) | 25/101 (25) | 0.88 |
SLEDAI at study point >12 | 6/143 (4) | 6/101(6) | 0.75 |